EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways

Sarfaraz K Niazi iD

Pharmaceuticals · 26.07.2025 · 18 (8) · 1115

DOI: 10.3390/ph18081115 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 26.07.2025. Verfasst von Sarfaraz K Niazi. Beteiligte Einrichtung: College of Pharmacy, University of Illinois, Chicago, IL 60612, USA. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The escalating global crisis of antimicrobial resistance, responsible for approximately 1.27 million deaths in 2019, has catalyzed renewed interest in bacteriophage therapy as a viable therapeutic alternative. With projections indicating that drug-resistant bacteria could cause over 39 million deaths worldwide by 2050, developing alternative antimicrobial strategies has become critically urgent. This comprehensive review examines the scientific foundation of bacteriophage therapy, traces its historical development from early Soviet applications through contemporary regulatory frameworks, and provides strategic guidance for developers seeking FDA approval for bacteriophage-based therapeutics. We analyze the current regulatory landscape across major jurisdictions, including manufacturing requirements and clinical development pathways essential for successful market authorization. Approximately 90 clinical trials involving bacteriophages are ongoing worldwide, with 41 studies in the United States demonstrating significant momentum in this field.

Schlagwörter

Stichwörter der Autor:innen

FDA approvalGMP manufacturingSoviet phage therapyantimicrobialantimicrobial resistancebacteriophage therapyclinical trialsinternational regulationregulatory pathway

Autor:innen und Institutionen

  • College of Pharmacy, University of Illinois, Chicago, IL 60612, USA.

ORCID-Profile: Sarfaraz K Niazi

Zitieren

APA

Niazi, S. K. (2025). Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways. Pharmaceuticals, 18(8), 1115. https://doi.org/10.3390/ph18081115

Vancouver

Niazi SK. Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways. Pharmaceuticals. 2025;18(8):1115. doi:10.3390/ph18081115

BibTeX
@article{Niazi2025,
  author = {Niazi, Sarfaraz K},
  title = {Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {8},
  pages = {1115},
  doi = {10.3390/ph18081115}
}
Kostenlos starten →